Literature DB >> 9687986

Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats.

M Landström1, J X Zhang, G Hallmans, P Aman, A Bergh, J E Damber, W Mazur, K Wähäla, H Adlercreutz.   

Abstract

METHODS: Dunning R3327 PAP prostate tumors were transplanted in 125 rats, the rats were divided into five groups, and tumor development was examined for 24 weeks during treatment with diets containing 33% of soy flour (SD), rye bran (RB), heat-treated rye bran (HRB), or rye endosperm (RE).
RESULTS: In the SD, RB, and HRB groups, significantly fewer palpable tumors and lower tumor volume were detected 14 and 16 weeks after transplantation when compared with the control, fiber-free dietary (FF) group. The body weight was lower 16 weeks after tumor transplantation in the RB and HRB groups when compared with the control group (P < 0.05). Rats in the RB and the HRB groups had a significant lower energy intake than the FF group during the first metabolic observation period, 3-6 weeks after tumor transplantation (P < 0.05), whereas the energy intake was the same in all groups during the second metabolic observation period, 13-16 weeks after tumor transplantation. However, when the tumor volume was adjusted for the body weight of the animals, there were still significant lower tumor volumes in the SD, RB, and HRB groups compared with the FF group (P < 0.05). A significant increase in daily urinary excretion of the isoflavonoids, daidzein, O-desmethylangolensin, equol, and Genistein, was observed in the rats fed SD, and of the ligands enterolactone and enterodiol in the rats fed RB and HRB during both metabolic periods. There were no differences in testosterone levels between the groups.
CONCLUSIONS: The present study shows that SD inhibits implanted prostate cancer growth. Although RB and HRB had a protective effect, further studies are needed to exclude the possibility that a low energy intake played a role in this respect. The results suggest that phytoestrogens (isoflavonoids and ligands), may be responsible for the delayed prostate tumor growth.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687986     DOI: 10.1002/(sici)1097-0045(19980801)36:3<151::aid-pros2>3.0.co;2-k

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  14 in total

Review 1.  [Chemoprevention of prostate cancer].

Authors:  B Djavan; I Thompson; M S Michel; M Waldert; C Seitz
Journal:  Urologe A       Date:  2004-05       Impact factor: 0.639

2.  Opportunities for prevention of prostate cancer: genetics, chemoprevention, and dietary intervention.

Authors:  Eric A Klein
Journal:  Rev Urol       Date:  2002

3.  COX-1 and -2 expressions in sex-related organs of neonatally estrogen-treated rats and in activated and nonactivated macrophage RAW264.7 cells with phytoestrogen.

Authors:  Cheng Luo; Ying Peng; Risto Santti; Ming Liang He; Marie C Lin
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

Review 4.  Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics.

Authors:  Fazlul H Sarkar; Yiwei Li
Journal:  Cancer Treat Rev       Date:  2009-08-05       Impact factor: 12.111

5.  A role for estrogen receptor beta in the regulation of growth of the ventral prostate.

Authors:  Z Weihua; S Makela; L C Andersson; S Salmi; S Saji; J I Webster; E V Jensen; S Nilsson; M Warner; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-22       Impact factor: 11.205

6.  The influence of hollyhock extract administration on testicular function in rats.

Authors:  Monika A Papiez
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

7.  Rye bread consumption in early life and reduced risk of advanced prostate cancer.

Authors:  Johanna E Torfadottir; Unnur A Valdimarsdottir; Lorelei Mucci; Meir Stampfer; Julie L Kasperzyk; Katja Fall; Laufey Tryggvadottir; Thor Aspelund; Orn Olafsson; Tamara B Harris; Eirikur Jonsson; Hrafn Tulinius; Hans-Olov Adami; Vilmundur Gudnason; Laufey Steingrimsdottir
Journal:  Cancer Causes Control       Date:  2012-04-25       Impact factor: 2.506

8.  Low body mass index is associated with adverse oncological outcomes following radical prostatectomy in Korean prostate cancer patients.

Authors:  Kyo Chul Koo; Young Eun Yoon; Koon Ho Rha; Byung Ha Chung; Seung Choul Yang; Sung Joon Hong
Journal:  Int Urol Nephrol       Date:  2014-05-10       Impact factor: 2.370

9.  2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways.

Authors:  Supriya Shah; Janet K Hess-Wilson; Siobhan Webb; Hannah Daly; Sonia Godoy-Tundidor; Jae Kim; Joanne Boldison; Yehia Daaka; Karen E Knudsen
Journal:  Mol Cancer Res       Date:  2008-09       Impact factor: 5.852

Review 10.  Multi-targeted therapy of cancer by genistein.

Authors:  Sanjeev Banerjee; Yiwei Li; Zhiwei Wang; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2008-05-19       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.